Sherene Min

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Sharon Walmsley, Antonio Antela, Nathan Clumeck et al. · New England Journal of Medicine · 2013 · 878 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet · 2013 · 546 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 514 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacotherapy +16

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Bonaventura Clotet, Judith Feinberg, Jan van Lunzen et al. · The Lancet · 2014 · 501 citations

Pharmacy, Infectious Diseases, Pharmacokinetics +12

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

François Raffi, Hans Jaeger, Eugenia Quirós-Roldán et al. · The Lancet Infectious Diseases · 2013 · 372 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11